Department of Pathology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong.
Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Anticancer Drugs. 2023 Apr 1;34(4):479-482. doi: 10.1097/CAD.0000000000001441. Epub 2022 Nov 17.
We have previously reported that patients with high Syndecan 1 (SDC1) expression in colorectal cancer (CRC) cells have a favorable prognosis, and we also found that stromal cells showed upregulation of SDC1, but the clinical significance is unclear. The expression of SDC1 in the stroma cells was assessed by immunohistochemistry using a tissue microarray comprising representative cores from 513 CRC patients. The correlation between the expression of SDC1 in the stroma cells and the clinicopathological features of patients was analyzed. The data showed that the expression of SDC1 in the stroma cells was correlated with the degree of differentiation ( P = 0.012) and tumor location (up or down) ( P = 0.005). Also, CRCs patients with high expression of SDC1 in the stromal cells have a good prognosis ( P = 0.0369). Accumulating evidence indicates that SDC1, whether in tumor cells or stromal cells, plays a tumor-suppressor role in CRCs.
我们之前报道过，结直肠癌细胞中高表达 Syndecan 1（SDC1）的患者预后良好，我们还发现基质细胞中 SDC1 呈上调表达，但临床意义尚不清楚。使用组织微阵列（包含 513 例 CRC 患者代表性核心的组织微阵列）通过免疫组织化学评估基质细胞中 SDC1 的表达。分析 SDC1 在基质细胞中的表达与患者临床病理特征之间的相关性。数据显示，基质细胞中 SDC1 的表达与分化程度（P=0.012）和肿瘤位置（上或下）（P=0.005）相关。此外，基质细胞中 SDC1 高表达的 CRC 患者预后良好（P=0.0369）。越来越多的证据表明，SDC1 无论是在肿瘤细胞还是基质细胞中，在 CRC 中都发挥着肿瘤抑制作用。
